111 related articles for article (PubMed ID: 31876587)
1. The Growing Problem of Hepatitis C Virus Infection: The Case of West Virginia.
Phillips M; Abboud J; Abodunde B; Paul DP; Coustasse A
Health Care Manag (Frederick); 2020; 39(1):2-11. PubMed ID: 31876587
[TBL] [Abstract][Full Text] [Related]
2. Liver disease burden and required treatment expenditures for hepatitis C virus (HCV) infection in Thailand: Implications for HCV elimination in the new therapeutic era, a population-based study.
Wasitthankasem R; Vichaiwattana P; Siripon N; Posuwan N; Auphimai C; Klinfueng S; Thanetkongtong N; Vuthitanachot V; Saiyatha S; Thongmai C; Sochoo S; Pongsuwan N; Poovorawan K; Tangkijvanich P; Poovorawan Y
PLoS One; 2018; 13(4):e0196301. PubMed ID: 29689073
[TBL] [Abstract][Full Text] [Related]
3. Long-term disease and economic outcomes of prior authorization criteria for Hepatitis C treatment in Pennsylvania Medicaid.
Kabiri M; Chhatwal J; Donohue JM; Roberts MS; James AE; Dunn MA; Gellad WF
Healthc (Amst); 2017 Sep; 5(3):105-111. PubMed ID: 27932263
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis C eradication: A long way to go.
Waheed Y
World J Gastroenterol; 2015 Nov; 21(43):12510-2. PubMed ID: 26604658
[TBL] [Abstract][Full Text] [Related]
5. Economic burden associated with patients diagnosed with hepatitis C.
McCombs JS; Yuan Y; Shin J; Saab S
Clin Ther; 2011 Sep; 33(9):1268-80. PubMed ID: 21840056
[TBL] [Abstract][Full Text] [Related]
6. Costs and cost-effectiveness of different follow-up schedules for detection of occupational hepatitis C virus infection.
Deuffic-Burban S; Abiteboul D; Lot F; Branger M; Bouvet E; Yazdanpanah Y
Gut; 2009 Jan; 58(1):105-10. PubMed ID: 18824553
[TBL] [Abstract][Full Text] [Related]
7. Increases in hepatitis C virus infection related to injection drug use among persons aged ≤30 years - Kentucky, Tennessee, Virginia, and West Virginia, 2006-2012.
Zibbell JE; Iqbal K; Patel RC; Suryaprasad A; Sanders KJ; Moore-Moravian L; Serrecchia J; Blankenship S; Ward JW; Holtzman D;
MMWR Morb Mortal Wkly Rep; 2015 May; 64(17):453-8. PubMed ID: 25950251
[TBL] [Abstract][Full Text] [Related]
8. Estimation of Hepatitis C Disease Burden and Budget Impact of Treatment Using Health Economic Modeling.
Chhatwal J; Chen Q; Aggarwal R
Infect Dis Clin North Am; 2018 Jun; 32(2):461-480. PubMed ID: 29778266
[TBL] [Abstract][Full Text] [Related]
9. NIH Consensus Statement on Management of Hepatitis C: 2002.
NIH Consens State Sci Statements; 2002 Jun 10-12; 19(3):1-46. PubMed ID: 14768714
[TBL] [Abstract][Full Text] [Related]
10. Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals.
Gountas I; Sypsa V; Papatheodoridis G; Souliotis K; Athanasakis K; Razavi H; Hatzakis A
World J Gastroenterol; 2019 Mar; 25(11):1327-1340. PubMed ID: 30918426
[TBL] [Abstract][Full Text] [Related]
11. Systematic review: economic evaluations of HCV screening in the direct-acting antivirals era.
Cortesi PA; Barca R; Giudicatti G; Mossini S; Ciaccio A; Iannazzo S; Micale M; Cesana G; Mantovani LG
Aliment Pharmacol Ther; 2019 May; 49(9):1126-1133. PubMed ID: 30843268
[TBL] [Abstract][Full Text] [Related]
12. A Success Story: Advances in Treatment and Lower Disease Prevalence of Hepatitis C Has a Large Impact on Medical Plan Costs.
Leung N; Bernacki SE; Bernacki EJ
J Occup Environ Med; 2019 Aug; 61(8):e354-e357. PubMed ID: 31205208
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis C Cure Is Associated with Decreased Healthcare Costs in Cirrhotics in Retrospective Veterans Affairs Cohort.
Maier MM; Zhou XH; Chapko M; Leipertz SL; Wang X; Beste LA
Dig Dis Sci; 2018 Jun; 63(6):1454-1462. PubMed ID: 29453610
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis C: epidemiology, diagnosis, natural history and therapy.
Pol S; Vallet-Pichard A; Corouge M; Mallet VO
Contrib Nephrol; 2012; 176():1-9. PubMed ID: 22310776
[TBL] [Abstract][Full Text] [Related]
15. A tool to measure the impact of inaction toward elimination of hepatitis C: A case study in Korea.
Won YK; Kang KS; Gonzalez YS; Razavi H; Dugan E; Han KH; Ahn SH; Jeon MY; Kim DY
PLoS One; 2020; 15(4):e0232186. PubMed ID: 32343727
[TBL] [Abstract][Full Text] [Related]
16. Drug Pricing Evolution in Hepatitis C.
Vernaz N; Girardin F; Goossens N; Brügger U; Riguzzi M; Perrier A; Negro F
PLoS One; 2016; 11(6):e0157098. PubMed ID: 27310294
[TBL] [Abstract][Full Text] [Related]
17. Characterization of the hepatitis C virus epidemic in Pakistan.
Mahmud S; Al Kanaani Z; Abu-Raddad LJ
BMC Infect Dis; 2019 Sep; 19(1):809. PubMed ID: 31521121
[TBL] [Abstract][Full Text] [Related]
18. Prioritization of high-cost new drugs for HCV: making sustainability ethical.
Craxì L; Sacchini D; Refolo P; Minacori R; Daloiso V; Ricci G; Bruno R; Cammà C; Cicchetti A; Gasbarrini A; Spagnolo AG
Eur Rev Med Pharmacol Sci; 2016; 20(6):1044-51. PubMed ID: 27049255
[TBL] [Abstract][Full Text] [Related]
19. New Therapies for Hepatitis C Virus.
Polenakovik H
Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2015; 36(2):119-32. PubMed ID: 27442378
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis C: an update on the silent epidemic.
Sarbah SA; Younossi ZM
J Clin Gastroenterol; 2000 Mar; 30(2):125-43. PubMed ID: 10730918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
